InspireMD, Inc. CFO Craig Shore to Retire, Company Initiates Search for SuccessorDecember 12, 2024-

InspireMD, Inc. (Nasdaq: NSPR) announced that Craig Shore, Chief Financial Officer (CFO), will be retiring from the company after a successor CFO is appointed. Until the successor assumes the role, Mr. Shore will continue to serve as CFO and will aid in facilitating a smooth transition in his responsibilities.

Marvin Slosman, Chief Executive Officer of InspireMD, expressed gratitude for Craig Shore’s dedicated 15-year tenure and his integral role in establishing the company as a global leader in carotid interventions. Slosman highlighted the significance of upcoming milestones, such as potential U.S. FDA approval in the first half of 2025, underscoring Shore’s decision as a reflection of confidence in the company’s trajectory and the evolving demands of a growing global enterprise.

A search has been initiated to identify the next Chief Financial Officer to succeed Mr. Shore. Additionally, on December 10, 2024, InspireMD and Mr. Shore executed the ninth amendment to their existing employment agreement, outlining adjustments pertaining to Mr. Shore’s termination without Cause.

As detailed in the amendment, in the event of a termination without Cause, Mr. Shore will receive entitled payments related to various compensatory benefits, including a one-time lump sum severance payment equivalent to 200% of his annual base salary, along with other benefits outlined in the agreement.

Furthermore, the Company disclosed its forward-looking statements, emphasizing that these projections are based on the present intentions, beliefs, or expectations of the company and cautioning investors against relying excessively on them.

In a press release dated December 12, 2024, the Company furnished details of Mr. Shore’s retirement and the impending CFO transition. For further information, the full press release is available as Exhibit 99.1 in this Current Report on Form 8-K.

Please note that the aforementioned descriptions do not encompass the comprehensive details of the Shore Amendment. The complete text of the Shore Amendment can be accessed in Exhibit 10.1 attached to this Current Report on Form 8-K.

Investors and interested parties are encouraged to review the Company’s filings with the Securities and Exchange Commission (SEC) for a detailed insight into the risk factors that could affect the actualization of the forward-looking statements made by the Company.

For any inquiries, please refer to the Investor Contacts provided in the Exhibit 99.1 section of this Current Report on Form 8-K.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read InspireMD’s 8K filing here.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.